Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Cultural and Genetic Diversity in America: The Need for Individualized Pharmaceutical Treatment

Pharmacogenetic research in the past few decades has uncovered significant differences among population groups in the metabolism, clinical effectiveness, and side effect profiles of many clinically important drugs. In addition, differences in how various populations view and respond to medicines underscores the need for an individualized approach to pharmaceutical therapy. Historically, the special needs and responses to pharmaceutical treatment of these groups have been undervalued or ignored. According to the authors, all of these factors must be taken into account in the design of cost management policies such as formulary management, therapeutic drug substitution, and step-care protocols. These programs should be broad and flexible enough to enable rational choices and individualized treatment for all patients, regardless of racial or ethnic origin.

Newsletter Volume

E.V.I.dently January 2016

MessageThe Importance of Evidence, Value, Access and Innovation in 2016In his annual health care outlook, NPC President Dan Leonard explains why...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Blog Post

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and...
Blog Post

The Shift to Value-Based Care: Balancing Quality Improvement with Patient Access

Over the last few years, there has been a significant shift throughout our health care system to move to a delivery and payment model known as value-...
Press Release

Improving Patient Outcomes and Costs in an ACO Through Comprehensive Medication Therapy Management

Washington, D.C. (December 4, 2014)—A case study published in the December 2014 issue of the Journal of Managed Care & Specialty Pharmacy...
Press Release

Specialty Medications: Shifting the Focus From “How Much” We Spend to “How Well” We Spend

Washington, DC, June 9, 2014—As health care decision-makers grapple with how to ensure access to specialty medications, the University of Michigan...
Press Release

NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied

Washington, DC, November 4, 2013—Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react...
Press Release

Pharmaceuticals Play Key Role in Achieving ACO Quality, Cost Goals

WASHINGTON, DC, July 18, 2012–As health care providers set up accountable care organizations (ACOs) and other value-based care programs,...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
Commentary and Testimony Page

Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals

Medications are more than an item on the balance sheet for health care providers. Pharmaceuticals offer a route to manage costs while achieving...
YouTube Videos

Anthem's Malin: Having Patient-Level Data Can Improve Clinical Care Pathways

The success of a clinical care pathway is related to the breadth and quality of the information that is available to organizations developing...
YouTube Videos

Anthem's Dr. Malin on Care Pathways: Their Implementation and Evaluation

Dr. Jennifer Malin, medical director, oncology and care management, Anthem, Inc., explains that her organization uses care pathways to address the...
YouTube Videos

Anthem's Dr. Malin on Clinical Care Pathways and Innovation

Could clinical care pathways help innovation? Anthem Inc.'s Dr. Jennifer Malin, medical director, oncology and care management, says it’s a strong...
YouTube Videos

Anthem's Malin: Communication Is Key to Success of Care Pathways

To make a clinical care pathway successful, “you have to work on many levels to engage providers,” says Dr. Jennifer Malin, medical director,...
Blog Post

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and...
Blog Post

The Shift to Value-Based Care: Balancing Quality Improvement with Patient Access

Over the last few years, there has been a significant shift throughout our health care system to move to a delivery and payment model known as value-...
Blog Post

#TBT: Restrictive Formularies & Potential Pitfalls

As part of our Throwback Thursday blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research,...
Blog Post

#TBT: 10 Prescribing Principles for Older Patients & #WHCOA

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
JCER

The Emerging Relevance of Heterogeneity of Treatment Effect in Clinical Care: A Study Using Stage IV Prostate Cancer as a Model

Although researchers and health care providers widely recognize that individuals with stage IV...

The Myth of Average: Why Individual Patient Differences Matter

Within today’s health care environment, so much of t

  •  
  • 1 of 39
  • >